iRhythm Technologies

iRhythm Technologies, Inc. engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It offers Zio XT, is a wearable patch-based biosensor, which continuously records and stores ECG data from every patient heartbeat for up to 14 consecutive days, and Zio AT, which provides ECG data but also provides physicians with actionable notifications during the wear period. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

iRhythm Technologies posts robust Q4 earnings, eyes global expansion

iRhythm Technologies delivered strong financial results, showcasing growth, innovation, and a positive EBITDA in Q4 2022. The company faces challenges in managing expenses and enhancing integration but has opportunities in new product launches, international expansion, and operational improvements.

iRhythm Technologies posts strong Q1 earnings amidst growth opportunities

iRhythm Technologies delivered robust Q1 2023 results with strong revenue growth and strategic advancements, positioning the company for sustainable expansion.
While challenges like legal inquiries and narrow profitability margins exist, the company's focus on innovation, market penetration, and financial stability bodes well for future prospects.
By capitalizing on strengths like positive clinical data, scalable growth strategies, and market opportunities, iRhythm Technologies aims to navigate challenges and drive long-term success.

iRhythm Technologies posts record revenue growth amidst regulatory challenges

iRhythm Technologies reported strong revenue growth and international expansion milestones despite challenges with FDA warning and product launch delays.
The company's focus on innovation, patient compliance, and market penetration presents opportunities for future growth and advocacy for proactive screening.
While facing challenges in product development and regulatory compliance, iRhythm remains financially robust and strategically positioned for continued success.
Navigating through challenges, iRhythm is poised to capitalize on growth opportunities and strengthen its position in the cardiac monitoring market.

iRhythm Technologies reports strong Q3 growth and eyes global expansion

iRhythm Technologies demonstrated strong financial performance in Q3 2023, with revenue growth, improved patient engagement, and market acceptance of Zio monitoring.
While facing challenges such as gross margin pressure and pricing concerns, iRhythm is focused on strategic growth initiatives and cost management for sustainable profitability.
The company is well-positioned to capitalize on opportunities like silent AFib monitoring, market expansion in Japan, and leveraging guidelines for wider screening to drive future growth.
Overall, iRhythm's Q3 results reflect resilience, strategic planning, and a positive outlook for continued success in 2023 and beyond.

iRhythm Technologies surpasses revenue expectations, eyes international expansion for growth

iRhythm Technologies demonstrated robust financial performance in Q4 2023, exceeding revenue guidance and showcasing growth in key operational metrics.
Despite regulatory challenges and external factors impacting revenue, the company's strategic strengths in product adoption and clinical evidence position it well for future growth.
Opportunities in AI, proactive screening, international expansion, and market disruption present avenues for continued expansion and market leadership.
Balancing challenges with opportunities, iRhythm aims to maintain financial sustainability while driving growth and innovation in the cardiac monitoring space.

iRhythm Technologies reports strong Q1 earnings, eyes global expansion

iRhythm Technologies delivered robust financial performance in Q1 2024, showcasing revenue growth, strategic partnerships, and a focus on sustainable operating leverage improvements.
While facing challenges such as awaiting FDA clearances and managing short-term financial losses, the company remains well-positioned with a strong financial foundation and global growth prospects.
Opportunities lie in upcoming product launches, market expansions, and the exploration of new adjacencies, positioning iRhythm for continued growth and market leadership.
Overall, iRhythm's emphasis on innovation, market expansion, and operational efficiency sets a positive trajectory for future success and shareholder value creation.

iRhythm Technologies excels in Q2 earnings, eyes global expansion

iRhythm Technologies delivered strong financial performance in Q2 2024, driven by product excellence and market expansion efforts.
While facing challenges with compliance and leadership transitions, the company remains focused on growth and operational effectiveness.
Strategic initiatives in primary care, new markets, and product launches position iRhythm well for future success and revenue growth.

iRhythm Technologies reports robust Q3 growth amidst regulatory advancements

iRhythm Technologies showed strong growth and strategic advancements in Q3 2024, focusing on global expansion and product innovation.
While facing financial challenges and regulatory hurdles, the company is actively addressing quality issues and investing in future growth.
Opportunities in international markets, product development, and financial optimization position iRhythm for long-term success and market leadership.
Investors should monitor iRhythm's progress in addressing challenges and capitalizing on growth opportunities for sustainable value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iRhythm Technologies, Inc. is a digital healthcare company, which engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

iRhythm Technologies Inc. (NASDAQ: IRTC) was up 20% after the digital healthcare solutions firm focusing on cardiac care advancement announced its financial results for the quarter ending March 31, 2022. iRhythm reports 24.3% revenue growth CEO and President Quentin Blackford said: Our strong first quarter results are indicative of the momentum we carried into 2022 […] The post Why iRhythm Technologies jumped 20% appeared first on Invezz.

Why iRhythm Technologies jumped 20%

iRhythm Technologies won a pair of lucrative reimbursement codes from Medicare, leading IRTC stock to rocket early Friday. The post Why Highly Rated iRhythm Technologies Is Making A 20% Jump Today appeared first on Investor's Business Daily.

Why Highly Rated iRhythm Technologies Is Making A 20% Jump Today

iRhythm Technologies Inc (NASDAQ: IRTC) posted Q1 sales of $92.4 million, up 24.3% Y/Y, beating the consensus of $86.76 million. The developer of remote external electrocardiogram monitors reported an adjusted EPS loss of $(0.80), above the consensus of $(1.08).

Investors Cheer Revised, Better Than Expected iRhythm's FY22 Outlook

IRhythm Technologies (IRTC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IRhythm Technologies (IRTC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

SAN FRANCISCO, April 21, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that it will release financial results for the first quarter 2022 after the close of trading on Thursday, May 5, 2022. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.

iRhythm Technologies to Report First Quarter 2022 Financial Results on May 5, 2022

Much as Intuitive Surgical redefined the surgical field, this company is updating how abnormal heart rhythms are diagnosed.

Missed Intuitive Surgical? Buy This Stock Instead

SAN FRANCISCO, April 03, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, announces the results of three clinical research studies presented at The American College of Cardiology's 71st Annual Scientific Session & Expo (ACC.22). The new clinical evidence:

Zio® by iRhythm Shown to Prevent Hospital Admissions, Aid in Early Detection of AF

Provides enhanced credit facility up to $100 million with favorable terms and facility maturity extended to March 2027 Provides enhanced credit facility up to $100 million with favorable terms and facility maturity extended to March 2027

iRhythm Technologies Announces Amendment to Term Loan Agreement

iRhythm Technologies (IRTC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

iRhythm Technologies (IRTC) Soars 4.3%: Is Further Upside Left in the Stock?

SAN FRANCISCO, March 14, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC) (“iRhythm”), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced that Kevin King will retire from iRhythm's Board of Directors effective April 1, 2022.

iRhythm® Technologies Announces Kevin King to Retire from Board of Directors

iRhythm Technologies (IRTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

iRhythm Technologies (IRTC) Upgraded to Buy: What Does It Mean for the Stock?

Additional clinical research shows bradyarrhythmias can be detected with 14-day cardiac monitoring through Zio XT before and after TAVR Additional clinical research shows bradyarrhythmias can be detected with 14-day cardiac monitoring through Zio XT before and after TAVR

Zio® by iRhythm Shows Significantly Higher Documentation of Atrial Fibrillation and Atrial Flutter Compared to Holter Monitors, Event Monitors

iRhythm Technologies, Inc. (IRTC) CEO Quentin Blackford on Q4 2021 Results - Earnings Call Transcript

SAN FRANCISCO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today reported financial results for the three months and full year ended December 31, 2021.

iRhythm Technologies Announces Fourth Quarter and Full Year 2021 Financial Results

SAN FRANCISCO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that it will release financial results for the fourth quarter and full year 2021 after the close of trading on Wednesday, February 23, 2022. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.

iRhythm Technologies to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

The stock price of iRhythm Technologies, a healthcare company that provides ambulatory electrocardiogram and cardiac monitoring products, has seen a rise of 20% over the last one month (twenty-one trading days). This can be attributed to Novitas, a Medicare Administrative Contractors (MACs).

Will IRhythm Technologies Stock Continue To See Higher Levels After A 20% Rally In A Month?

iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in iRhythm Technologies (IRTC): Can Its 27.6% Jump Turn into More Strength?

SAN FRANCISCO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, commented on ​​the recent update by Novitas Solutions (Novitas), a Medicare Administrative Contractor (MAC), regarding updated rates applicable to the Current Procedural Terminology (CPT) codes 93243 and 93247.

iRhythm Technologies Comments on Medicare Administrative Contractor 2022 Rate Update

Irhythm Technologies (IRTC) stock is rising higher Monday alongside heavy trading of the shares and we know what's behind that movement! The post IRTC Stock: 17 Things to Know About iRhythm as Shares Rocket Higher Today appeared first on InvestorPlace.

IRTC Stock: 17 Things to Know About iRhythm as Shares Rocket Higher Today

SAN FRANCISCO, Dec. 29, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the company will be participating in the upcoming 40th Annual J.P. Morgan Healthcare Conference.

iRhythm® Technologies to Present at the 40th Annual J.P. Morgan Healthcare Conference

iRhythm Technologies' (IRTC) CEO Quentin Blackford on Q3 2021 Results - Earnings Call Transcript

Wearable electrocardiograph patch maker IRhythm Technologies Inc's (NASDAQ: IRTC) lowered its revenue guidance for 2021 due to unforeseen impacts related to the COVID-19 Delta variant, customer staffing challenges, and delayed account launches and expansion.  It expects sales of $317 million - $319 million (consensus $323.46 million) dropped from a previous estimate of $320 million - $325 million.

IRhythm Stock Falls On Lowered Sales Guidance

Karyopharm Therapeutics

Regeneron Pharmaceuticals

Tyra Biosciences

Could these health care stocks be buys on President Biden's latest vaccine mandate?

4 Health Care Stocks For Your November 2021 Watchlist

Investors think that new Medicare payment guidelines will benefit the company.

Why iRhythm Technologies Stock Skyrocketed Today

iRhythm Technologies Inc (NASDAQ: IRTC) commented on the CMS (Centers for Medicare and Medicaid Services) Calendar Year 2022 Medicare Physician Fee Schedule (MPFS) Final Rule. In the Final Rule, CMS did not issue national pricing and continued carrier pricing on Category I CPT codes 93241, 93243, 93245, and 93247 for extended external ECG (electrocardiograph) monitoring, the relevant codes for the Company's Zio XT service.

News for iRhythm Technologies Stock (IRTC)